<script type="text/javascript">
<!--
document.write('<div id="oa_widget"></div>');
document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=undefined&type=result"></script>');
-->
</script>

COPY SCRIPT

For further information contact us at helpdesk@openaire.eu

Neoplasm to Neoplasm Metastasis

A Renal Oncocytoma with Metastatic Bronchogenic Carcinoma

descriptionPublicationkeyboard_double_arrow_right Article 01 Jan 1984 English Publisher:Informa UK LimitedJournal:Scandinavian Journal of Urology and Nephrology, volume 18, pages 255-256 (issn: 0036-5599, eissn: 1651-2065,

Authors: Ole Skat Nielsen; Ulla Engel; Jens Olsen;

doi: 10.3109/00365598409180193

pmid: 6093242

Neoplasm to Neoplasm Metastasis

- Summary
- Subjects
- Metrics

Abstract

An unusual case of metastasis of neoplasm to a benign neoplasm is reported. The initial malignancy, a small-cell bronchogenic carcinoma, was found to have metastasis to a renal oncocytoma. A review of the literature indicates, according to our knowledge, no similar case.

Related Organizations

Keywords

Adenoma, Male, Lung Neoplasms, Brain Neoplasms, Carcinoma, Liver Neoplasms, Kidney Neoplasms, Carcinoma, Bronchogenic, Humans, Carcinoma, Small Cell, Neoplasm Metastasis, Aged

Impact byBIP!

	citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	34
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Top 10%
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Top 10%